10-Q · May 26, 2026
Apimeds Pharmaceuticals US, Inc. reported Q4 results showing zero revenue and an EPS of -0.8, marking a significant increase in operating losses compared to the prior year. The company raised concerns over its…
Earnings analysis · 10-Q
APUS earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so current-period revenue, margins, EPS, free cash flow, and period-over-period trends…
Read full summary
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so current-period revenue, margins, EPS, free cash flow, and period-over-period trends cannot be quantified from the filing text supplied. The filing highlights substantial financial and operating risk: digital assets were 89% of total assets, a 10% decline in their value would have increased net loss by approximately $11.7 million, and $5.0 million of notes payable matured on July 1, 2026. The company also reports substantial doubt about going-concern status, ineffective disclosure controls, and NYSE American compliance risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Emerson Litigation Dismissed
The litigation captioned Erik Emerson v. Inscobee Inc. and Apimeds, Inc. was voluntarily dismissed on May 5, 2026; the filing states that no amounts were paid and no liability was recorded.
-
Reverse Split Completed
The company completed a 1-for-10 reverse stock split effective July 23, 2026, potentially supporting compliance with listing requirements, although the filing warns of possible adverse liquidity and market-price effects.
-
Settlement Agreement Executed
The previously disclosed litigation settlement was entered into on April 24, 2026, and management states that the related Settlement Agreement did not alter internal-control design or operation during the quarter.
What to watch
-
Extreme Digital-Asset Concentration
Digital assets represented 89% of total assets as of June 30, 2026. The filing states that a hypothetical 10% decline in digital-asset fair value would have reduced total assets and increased net loss by approximately $11.7 million.
-
Matured Debt and Going Concern
Substantial doubt exists about the company’s ability to continue as a going concern. Notes payable with aggregate principal of $5,000,000 matured on July 1, 2026, while the senior secured convertible-note forbearance expired on June 30, 2026; the company remained in discussions regarding extension or restructuring.
-
NYSE American Delisting Risk
The company is not in compliance with Section 1007 of the NYSE American Company Guide and could be delisted if it does not regain compliance within the cure period. The filing also states that the 1-for-10 reverse split may adversely affect liquidity and market price.
-
Material Control Weaknesses
Disclosure controls and procedures were ineffective as of June 30, 2026 because of material weaknesses involving qualified accounting personnel, journal-entry review, reconciliations, risk assessment, segregation of duties, and accounting for complex transactions.
Management's outlook
The provided 10-Q text does not include quantitative revenue or EPS guidance. No explicit forward outlook was provided; management is instead discussing extensions or restructuring of obligations that matured on July 1, 2026.
Earlier filings 2
10-K · May 4, 2026
Apimeds Pharmaceuticals US, Inc. reported significant developments in its strategic direction, primarily focused on advancing its biopharmaceutical pipeline and its digital asset segment following the acquisition of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.